The Definitive Guide to DuP-697
All enrolled sufferers who been given at the least one dose of zosuquidar or placebo all through induction had been monitored to the occurrence of adverse occasions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most typical adverse situations were connected with the period of extended and significant myelosuppression as is anticipated